Johnson & Johnson $JNJ Position Trimmed by West Oak Capital LLC

West Oak Capital LLC reduced its holdings in Johnson & Johnson (NYSE:JNJ) by 79.1% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 3,750 shares of the company’s stock after selling 14,228 shares during the quarter. West Oak Capital LLC’s holdings in Johnson & Johnson were worth $695,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of JNJ. Shorepoint Capital Partners LLC acquired a new stake in shares of Johnson & Johnson during the 3rd quarter worth approximately $6,434,000. St. Louis Financial Planners Asset Management LLC bought a new position in Johnson & Johnson during the 3rd quarter worth $3,072,000. GAMMA Investing LLC lifted its stake in Johnson & Johnson by 10.4% in the third quarter. GAMMA Investing LLC now owns 54,509 shares of the company’s stock valued at $10,107,000 after buying an additional 5,142 shares during the last quarter. First Hawaiian Bank boosted its holdings in shares of Johnson & Johnson by 26.5% during the third quarter. First Hawaiian Bank now owns 1,879 shares of the company’s stock valued at $348,000 after acquiring an additional 394 shares during the period. Finally, Capital Asset Advisory Services LLC boosted its holdings in shares of Johnson & Johnson by 5.1% during the third quarter. Capital Asset Advisory Services LLC now owns 27,635 shares of the company’s stock valued at $5,124,000 after acquiring an additional 1,335 shares during the period. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $214.41 on Tuesday. The company has a market capitalization of $516.58 billion, a PE ratio of 20.70, a price-to-earnings-growth ratio of 2.36 and a beta of 0.36. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. The stock has a fifty day moving average of $196.61 and a 200-day moving average of $177.85. Johnson & Johnson has a one year low of $140.68 and a one year high of $215.19.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The company had revenue of $24.02 billion for the quarter. As a group, equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th were issued a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.4%. The ex-dividend date was Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 50.19%.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on JNJ. Raymond James Financial lifted their price objective on shares of Johnson & Johnson from $174.00 to $209.00 and gave the company an “outperform” rating in a research report on Wednesday, October 15th. Guggenheim raised their target price on Johnson & Johnson from $206.00 to $227.00 and gave the company a “buy” rating in a research report on Friday, December 5th. JPMorgan Chase & Co. boosted their price target on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a “neutral” rating in a research report on Tuesday, September 16th. UBS Group boosted their target price on Johnson & Johnson from $190.00 to $214.00 and gave the stock a “buy” rating in a report on Tuesday, October 14th. Finally, Scotiabank assumed coverage on Johnson & Johnson in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $230.00 target price for the company. Four investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average target price of $208.35.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.